Welcome to the new scientist and researcher reference section. Your one-stop shop for the essential resources you need to advance your career.

Upcoming Meetings

SNMMI 2019 Annual Meeting

June 22-25, 2019 | Anaheim, California
Book Your HotelExhibit HallRegistration Information

Choose from more than 200 Educational Sessions!
The SNMMI 2019 Annual Meeting—featuring eight categorical seminars, more than 120 CE and 80 scientifi c sessions, as well as several specialty workshops and an extensive scientific poster hall—will provide you with an in-depth view of the latest research, development, and clinical applications helping to advance targeted, personalized medicine.

Celebrating Past and Future Innovations in Instrumentation
In the 60 years since the introduction of the Anger Camera, the development of new state-ofthe-art instrumentation has been at the heart of nuclear medicine progress. The plenary sessions will showcase speakers who are true innovators in nuclear medicine instrumentation.

Highlight Country: Canada
SNMMI is pleased to welcome Canada as this year’s Highlight Country. The Canadian Nuclear Medicine Association present at the Opening Ceremony, organize four continuing education sessions, and introduce attendees to aspects of Canadian culture.

Taking in the Southern California Lifestyle
Anaheim - with its convenient Southern California location, beautiful weather, and wide variety of activities - is the perfect host city for our meeting. Home to Disneyland, the Los Angeles Angels and their legendary stadium, the Big A, the fourth oldest baseball stadium in major league baseball, Anaheim’s central location serves as a convenient gateway to Orange County’s 42 miles of Pacific Ocean coastline, luxury shopping, championship golf courses, and terrain for hiking, biking, running, and sunning.


Coding and Reimbursement

The most up-to-date and comprehensive source for nuclear medicine coding and reimbursement information on the web. Please note that ALL information and materials within the SNMMI Coding Corner are direct products of the SNMMI Coding and Reimbursement Working Group.

For Hospitals (APCs, IPPS) Find general coding and reimbursement information for hospitals.

For Private Practices (RBRVS) Find general coding and reimbursement information for professionals in private practices.

Coding and Reimbursement Q&A This easy to use feature contains over 100 questions and answers related to topics such as cardiac, endocrine, neurology, nuclear medicine-related drugs, oncology, PET, PET/CT, radiopharmaceuticals, and more!

Dose Optimization

In nuclear medicine and molecular imaging, small amounts of radioactive agents are administered to the patient to allow the physician to examine molecular processes within the body. These procedures are highly effective, safe and painless diagnostic tools that present physicians with a detailed view of what’s going on inside an individual’s body at the cellular level. For more than 60 years, these studies have been used to evaluate practically all systems within the body, including the heart and brain, as well as to image many types of cancer.

SNMMI has a large body of knowledge in dose optimization that is continually growing and developing. The dose optimization website presents a wide variety of resources, including SNMMI journal articles, educational offerings, media-related information, links to useful websites and more.



The practice guidelines help to identify those elements of the procedure that are most important in obtaining a high-quality examination, while simultaneously controlling costs. Use of standardized procedures will increase the applicability of clinical research among multiple institutions, in turn, increasing the value of research studies, particularly in the field of technology assessment. In the interest of creating strong, comprehensive documents, some guidelines were formally adopted by SNMMI in collaboration with other professional organizations.

View Guidelines.

Focusing on the Future of Molecular Imaging

SNMMI's Center for Molecular Imaging Innovation and Translation is an organizational component within the SNMMI that is dedicated to all aspects of molecular imaging in the detection and management of disease. The center is currently facilitating initiatives to bring molecular imaging discoveries from the lab to the patient and to advance "personalized" medicine.

Access resources.

The Clinical Trials Network’s mission is to advance the use of molecular imaging radiopharmaceuticals in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new agents to regulatory approval. Click here to learn more about the CTN’s Oncology and Neurology Scanner Validation programs, ongoing efforts to harmonize reconstruction parameters in oncology clinical trials, and other services that CTN offers to help scientists advance their research.

Educational Offerings

SNMMI educational programs are designed to meet the professional development needs of scientists involved in nuclear medicine and molecular imaging endeavors. 

Visit the SNMMI Learning Center.

Additional Resources

  • April 8, 2019SNMMI and ACR Collaborate on Clinical Data Registry for Nuclear Medicine

    SNMMI and the American College of Radiology announce a new collaborative clinical data registry to support high-quality practice and patient care. The registry will allow collection and analysis of data on nuclear medicine procedures, supporting continuous improvement of patient care.
    (Press Release)

  • April 4, 2019SNMMI/ASNC Alert: Important Drug Safety Information for Rubidium 82 Generators

    Recently, there has been a report of high-level radiation exposure with use of incorrect eluent in Rubidium 82 Rb82 generators after a failure to follow the eluate testing protocol. ASNC and SNMMI members are reminded to use only additive-free, 0.9 % Sodium Chloride Injection, USP (normal saline) to elute the Rubidium 82 Rb82 generator.
    (Government Relations News)

  • April 4, 2019New PET Imaging Biomarker Could Better Predict Progression of Alzheimer’s Disease

    Researchers have discovered a way to better predict progression of Alzheimer’s disease. A study utilizing positron emission tomography to image microglial activation levels showed that these levels could predict current and future cognitive performance better than beta-amyloid levels. The research is published in the April issue of The Journal of Nuclear Medicine.
    (Press Release)

  • April 1, 2019This Month in JNM

    The April 2019 issue of The Journal of Nuclear Medicine is now available, including a discussion with Michael Phelps, a State of the Art column on precision cardio-oncology, a special contribution on tumor glucose metabolism, results of an international survey on clinical reporting of PET/CT examinations, and featured articles on a new PET biomarker for predicting progression of Alzheimer’s, a 12-year retrospective follow-up on PRRT for NETs, and substrate anti-cancer drug delivery
    (SNMMI News)


Featured Resources